By a GenomeWeb Staff Reporter

NEW YORK (GenomeWeb News) – UK phosphoproteomics firm Activiomics today announced it has received a £500,000 ($806,715) investment, which it will use to further build partnerships with pharmaceutical and biotech firms and to identify novel biomarkers.

Leading the round was IP Group. Additional investors included IP Venture Fund and members of Activiomics' management.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: rare variants linked to bleeding disorder, comparison of whole-exome and whole-genome sequencing, and more.

George Church tells The Sunday Times that his group has inserted some woolly mammoth genes into elephant cells.

A Scientific Reports editor resigns over a new policy at the journal allowing researchers to pay to fast track the peer review of their manuscripts, and poll.

The National Cancer Institute's Harold Varmus discusses the state of cancer research with the New York Times.